Skip to main content
A National Spinal Muscular Atrophy Registry for Real-World Evidence.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • Victoria L Hodgkinson
  • Maryam Oskoui
  • Joshua Lounsberry
  • Saïd M'Dahoma
  • Emily Butler
  • Craig Campbell
  • Alex MacKenzie
  • Hugh J McMillan
  • Louise Simard
  • Jiri Vajsar
  • Bernard Brais
  • Kristine M Chapman
  • Nicolas Chrestian
  • Meghan Crone
  • Peter Dobrowolski
  • Susan Dojeiji
  • James J Dowling
  • Nicolas Dupré
  • Angela Genge
  • Hernan Gonorazky
  • Simona Hasal
  • Aaron Izenberg
  • Wendy Johnston
  • Edward Leung
  • Hanns Lochmüller
  • Jean K Mah
  • Alier Marerro
  • Rami Massie
  • Laura McAdam
  • Anna McCormick
  • Michel Melanson
  • Michelle M Mezei
  • Cam-Tu E Nguyen
  • Colleen O'Connell
  • Erin K O'Ferrall
  • Gerald Pfeffer
  • Cecile Phan
  • Stephanie Plamondon
  • Chantal Poulin
  • Xavier Rodrigue
  • Kerri L Schellenberg
  • Kathy Selby
  • Jordan Sheriko
  • Christen Shoesmith
  • Garth Smith
  • Monique Taillon
  • Sean Taylor
  • Jodi Warman Chardon
  • Scott Worley
  • Lawrence Korngut
Document Type
Publication Date
URL with Digital Object Identifier

BACKGROUND: Spinal muscular atrophy (SMA) is a devastating rare disease that affects individuals regardless of ethnicity, gender, and age. The first-approved disease-modifying therapy for SMA, nusinursen, was approved by Health Canada, as well as by American and European regulatory agencies following positive clinical trial outcomes. The trials were conducted in a narrow pediatric population defined by age, severity, and genotype. Broad approval of therapy necessitates close follow-up of potential rare adverse events and effectiveness in the larger real-world population.

METHODS: The Canadian Neuromuscular Disease Registry (CNDR) undertook an iterative multi-stakeholder process to expand the existing SMA dataset to capture items relevant to patient outcomes in a post-marketing environment. The CNDR SMA expanded registry is a longitudinal, prospective, observational study of patients with SMA in Canada designed to evaluate the safety and effectiveness of novel therapies and provide practical information unattainable in trials.

RESULTS: The consensus expanded dataset includes items that address therapy effectiveness and safety and is collected in a multicenter, prospective, observational study, including SMA patients regardless of therapeutic status. The expanded dataset is aligned with global datasets to facilitate collaboration. Additionally, consensus dataset development aimed to standardize appropriate outcome measures across the network and broader Canadian community. Prospective outcome studies, data use, and analyses are independent of the funding partner.

CONCLUSION: Prospective outcome data collected will provide results on safety and effectiveness in a post-therapy approval era. These data are essential to inform improvements in care and access to therapy for all SMA patients.

Creative Commons License
Creative Commons Attribution 4.0
Citation Information
Victoria L Hodgkinson, Maryam Oskoui, Joshua Lounsberry, Saïd M'Dahoma, et al.. "A National Spinal Muscular Atrophy Registry for Real-World Evidence." The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques Vol. 47 Iss. 6 (2020) p. 810 - 815
Available at: